BRPI0922867A2 - proteina de fusao (f) de virus sincicial respiratorio (rsv) e metodos para seu uso - Google Patents

proteina de fusao (f) de virus sincicial respiratorio (rsv) e metodos para seu uso

Info

Publication number
BRPI0922867A2
BRPI0922867A2 BRPI0922867A BRPI0922867A BRPI0922867A2 BR PI0922867 A2 BRPI0922867 A2 BR PI0922867A2 BR PI0922867 A BRPI0922867 A BR PI0922867A BR PI0922867 A BRPI0922867 A BR PI0922867A BR PI0922867 A2 BRPI0922867 A2 BR PI0922867A2
Authority
BR
Brazil
Prior art keywords
fsv
methods
fusion protein
respiratory syncytial
syncytial virus
Prior art date
Application number
BRPI0922867A
Other languages
English (en)
Inventor
Bin Zhou
Gale Smith
Michael Massare
Peter Pushko
Ye Liu
Yingyun Wu
Original Assignee
Novavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42310119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0922867(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novavax Inc filed Critical Novavax Inc
Publication of BRPI0922867A2 publication Critical patent/BRPI0922867A2/pt
Publication of BRPI0922867B1 publication Critical patent/BRPI0922867B1/pt
Publication of BRPI0922867B8 publication Critical patent/BRPI0922867B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/155Paramyxoviridae, e.g. parainfluenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18523Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561Methods of inactivation or attenuation
    • C12N2760/18562Methods of inactivation or attenuation by genetic engineering
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18571Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0922867A 2008-12-09 2009-12-09 glicoproteina de fusão (f) de vírus sincicial respiratório (rsv), ácido nucleico isolado, célula hospedeira, composição de vacina e micela purificada BRPI0922867B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US12112608P 2008-12-09 2008-12-09
US61/121,126 2008-12-09
US16907709P 2009-04-14 2009-04-14
US61/169,077 2009-04-14
US22478709P 2009-07-10 2009-07-10
US61/224,787 2009-07-10
PCT/US2009/067269 WO2010077717A1 (en) 2008-12-09 2009-12-09 Modified rsv f proteins and methods of their use

Publications (3)

Publication Number Publication Date
BRPI0922867A2 true BRPI0922867A2 (pt) 2016-09-27
BRPI0922867B1 BRPI0922867B1 (pt) 2020-09-29
BRPI0922867B8 BRPI0922867B8 (pt) 2021-05-25

Family

ID=42310119

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0922867A BRPI0922867B8 (pt) 2008-12-09 2009-12-09 glicoproteina de fusão (f) de vírus sincicial respiratório (rsv), ácido nucleico isolado, célula hospedeira, composição de vacina e micela purificada

Country Status (23)

Country Link
US (7) US8715692B2 (pt)
EP (3) EP3067064B1 (pt)
JP (4) JP5813513B2 (pt)
KR (2) KR101801213B1 (pt)
CN (2) CN102307591B (pt)
AU (1) AU2009333484B2 (pt)
BR (1) BRPI0922867B8 (pt)
CA (1) CA2746228C (pt)
CY (2) CY1117757T1 (pt)
DK (2) DK3067064T3 (pt)
ES (2) ES2796725T3 (pt)
HK (1) HK1161690A1 (pt)
HR (2) HRP20160859T1 (pt)
HU (2) HUE051666T2 (pt)
IL (2) IL213450B (pt)
LT (1) LT3067064T (pt)
MX (4) MX2011006205A (pt)
PL (2) PL2370099T3 (pt)
PT (2) PT2370099T (pt)
RU (1) RU2531510C2 (pt)
SG (2) SG10201500161XA (pt)
SI (2) SI2370099T1 (pt)
WO (1) WO2010077717A1 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160000902A1 (en) * 2003-07-11 2016-01-07 Novavax, Inc. Combination vaccine for respiratory syncytial virus and influenza
EP2367844A4 (en) * 2008-11-18 2012-08-01 Ligocyte Pharmaceuticals Inc RSV-F VLP AND MANUFACTURING METHOD AND METHOD OF USE THEREOF
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
MX2011006205A (es) * 2008-12-09 2011-09-01 Novavax Inc Proteinas f del vrs modificadas y metodos de uso de las mismas.
HRP20220756T1 (hr) * 2009-07-15 2022-09-02 Glaxosmithkline Biologicals S.A. Proteinski pripravci rsv f i postupci za izradu istih
US20110097358A1 (en) * 2009-10-12 2011-04-28 Techno Vax, Inc. RESPIRATORY SYNCYTIAL VIRUS (RSV) VIRUS-LIKE PARTICLES (VLPs)
HUE034247T2 (en) * 2010-11-05 2018-02-28 Novavax Inc Rabies glycoprotein virus-like particles (VLP-K)
WO2012089231A1 (en) * 2010-12-30 2012-07-05 Okairòs Ag Paramyxovirus vaccines
TR201908715T4 (tr) 2011-01-26 2019-07-22 Glaxosmithkline Biologicals Sa Rsv immünizasyon rejimi.
EP2739307B1 (en) * 2011-08-01 2017-09-06 Emory University Vlps containing ligands and methods related thereto
JP6085886B2 (ja) 2011-08-29 2017-03-01 国立大学法人徳島大学 Rsv粘膜ワクチン
SG10201602434UA (en) * 2011-09-30 2016-05-30 Novavax Inc Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus
CN103239734B (zh) * 2012-02-10 2016-02-24 北京艾棣维欣生物技术有限公司 用于预防和/或治疗呼吸道合胞病毒感染的疫苗
JP6523955B2 (ja) 2012-08-01 2019-06-05 バヴァリアン・ノルディック・アクティーゼルスカブ 組換え改変ワクシニアウイルスアンカラ(mva)rsウイルス(rsv)ワクチン
EP2922570A1 (en) 2012-11-20 2015-09-30 GlaxoSmithKline Biologicals SA Rsv f prefusion trimers
RU2015138530A (ru) * 2013-02-11 2017-03-20 Новавакс, Инк. Комбинированная вакцина против респираторно-синцитиального вируса и вируса гриппа
DE102013004595A1 (de) * 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
CN105555306B (zh) 2013-09-19 2019-12-03 诺瓦瓦克斯股份有限公司 免疫原性中东呼吸综合征冠状病毒(MERS-CoV)组合物和方法
EP2974739A1 (en) 2014-07-15 2016-01-20 Novartis AG RSVF trimerization domains
WO2015195961A1 (en) * 2014-06-18 2015-12-23 Georgia State University And Research Foundation, Inc. Recombinant rsv reporter virus
TWI720946B (zh) * 2014-08-08 2021-03-11 美商Vlp醫療股份有限公司 包含改質套膜蛋白質e3之類病毒粒子
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
KR102638978B1 (ko) 2015-07-07 2024-02-22 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 백신
CN114796474A (zh) * 2015-09-03 2022-07-29 诺瓦瓦克斯股份有限公司 具有改进的稳定性和免疫原性的疫苗组合物
RU2723039C2 (ru) 2015-12-23 2020-06-08 Пфайзер Инк. Мутанты белка f rsv
CA3018139A1 (en) 2016-04-05 2017-10-12 Janssen Vaccines & Prevention B.V. Vaccine against rsv
KR102421049B1 (ko) 2016-05-30 2022-07-15 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 융합-전 rsv f 단백질
CN106011086A (zh) * 2016-06-15 2016-10-12 湖北省农业科学院畜牧兽医研究所 表达信号肽替换的呼吸道合胞病毒f蛋白的重组新城疫耐热疫苗株及制备方法
MA47787A (fr) * 2017-03-15 2020-01-22 Modernatx Inc Vaccin contre le virus respiratoire syncytial
SG11201908280SA (en) 2017-03-30 2019-10-30 Univ Queensland "chimeric molecules and uses thereof"
RU2019130167A (ru) 2017-04-04 2021-05-05 Юниверсити Оф Вашингтон Самосборные белковые наноструктуры, экспонирующие f-белки парамиксовируса и/или пневмовируса, и их применение
KR20200018483A (ko) 2017-06-14 2020-02-19 비로메틱스 아게 호흡기 합포체 바이러스에 대한 방어를 위한 고리형 펩티드
CN111148509A (zh) 2017-07-24 2020-05-12 诺瓦瓦克斯股份有限公司 治疗呼吸系统疾病的方法和组合物
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
CN112088014A (zh) 2018-02-28 2020-12-15 华盛顿大学 自组装纳米结构疫苗
SG11202009206QA (en) 2018-03-19 2020-10-29 Novavax Inc Multivalent influenza nanoparticle vaccines
EP3775174A4 (en) * 2018-03-30 2022-07-06 Georgia State University Research Foundation, Inc. RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINES
EP3773704A1 (en) 2018-04-03 2021-02-17 Sanofi Antigenic respiratory syncytial virus polypeptides
KR20200050264A (ko) * 2018-11-01 2020-05-11 에스케이바이오사이언스(주) 재조합 호흡기 세포융합 바이러스 f 단백질 및 이를 포함하는 백신 조성물
WO2020127728A1 (en) 2018-12-20 2020-06-25 Virometix Ag Lipopeptide building blocks and synthetic virus-like particles
WO2020175660A1 (ja) 2019-02-28 2020-09-03 Kmバイオロジクス株式会社 Rsv f/gキメラワクチン
BR112022014830A2 (pt) * 2020-01-27 2022-09-27 Novavax Inc Formulações de vacina para coronavírus
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
CA3174215A1 (en) 2020-04-22 2021-10-28 Ugur Sahin Coronavirus vaccine
CN113855796B (zh) * 2021-07-30 2024-01-26 河北医科大学 卡介苗作为呼吸道合胞病毒灭活疫苗佐剂的应用
WO2023062651A1 (en) * 2021-10-13 2023-04-20 Padmanabh Patil Harshad Virus-like particles for respiratory syncytial virus and method of preparation thereof
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
CN115927751A (zh) * 2022-09-17 2023-04-07 宁夏大学 牛呼吸道合胞体病毒实时荧光定量pcr检测的引物探针组及检测方法
CN118078975A (zh) * 2023-03-17 2024-05-28 成都威斯克生物医药有限公司 抗呼吸道合胞病毒感染的疫苗
CN118146321B (zh) * 2024-03-27 2024-08-27 普大生物科技(泰州)有限公司 一种rsv重组蛋白疫苗及其制备方法
CN118480560A (zh) * 2024-07-09 2024-08-13 北京悦康科创医药科技股份有限公司 呼吸道合胞病毒mRNA疫苗及其制备方法和应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149650A (en) 1986-01-14 1992-09-22 University Of North Carolina At Chapel Hill Vaccines for human respiratory virus
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
GB8914968D0 (en) * 1989-06-29 1989-08-23 Connaught Lab Production of virus and purification of viral envelope proteins for vaccine use
US6387373B1 (en) 1993-01-15 2002-05-14 Novavax, Inc. Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants
ES2370937T3 (es) 1993-09-13 2011-12-23 Protein Sciences Corporation Un método para producir vacunas antigripales polivalentes a base de hemaglutinina.
US5629021A (en) 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
US6020182A (en) * 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
CA2399321C (en) 2000-03-07 2013-04-30 Robert K. Evans Adenovirus formulations
AR030829A1 (es) 2000-10-02 2003-09-03 Smithkline Beecham Biolog Una formulacion de vacuna, procedimiento para la produccion de la misma, uso de dicha preparacion y un estuche para su administracion via intranasal
US20040063188A1 (en) 2002-02-14 2004-04-01 Novavax, Inc. Kit for treating gastrointestinal tract
AU2004273776B2 (en) 2003-04-25 2010-07-08 Medimmune, Llc Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
EP1668112A4 (en) * 2003-06-20 2009-04-29 Protein Sciences Corp SARS IMMUNOGENOUS EXPRESSING VECTORS, SUCH VECTORS OR EXPRESSION PRODUCTS COMPRISING THOSE COMPOSITIONS, PROCESSES AND TESTS FOR THE PREPARATION AND USE THEREOF
EP1713824A2 (en) 2003-12-10 2006-10-25 The Uab Research Foundation Recombinant viruses with heterologous envelope proteins
WO2006099360A2 (en) 2005-03-10 2006-09-21 Medimmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
WO2007149490A1 (en) 2006-06-19 2007-12-27 Progenics Pharmaceuticals, Inc. Processes for recovering stabilized formulations of trimers of retroviral envelope (env) proteins
US20080233150A1 (en) * 2006-11-16 2008-09-25 Gale Smith Respiratory syncytial virus-virus like particle (vlps)
US8772256B2 (en) * 2006-11-30 2014-07-08 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Codon modified immunogenic compositions and methods of use
EP1972348A1 (en) * 2007-03-14 2008-09-24 Pierre Fabre Medicament Novel vaccine composition for the treatment of respiratory infectious diseases
JP2010522540A (ja) * 2007-03-21 2010-07-08 アイディー バイオメディカル コーポレイション オブ ケベック キメラ抗原
JP2010533737A (ja) 2007-07-19 2010-10-28 ノババックス,インコーポレイテッド キメラ水痘帯状疱疹ウイルス−ウイルス様粒子
EP4206231A1 (en) 2007-12-24 2023-07-05 ID Biomedical Corporation of Quebec Recombinant rsv antigens
BRPI0908861A2 (pt) 2008-02-25 2018-02-06 Novavax Inc partículas semelhantes a vírus de açucar vitrificado (vlps)
MX2011006205A (es) 2008-12-09 2011-09-01 Novavax Inc Proteinas f del vrs modificadas y metodos de uso de las mismas.
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
CN107252482A (zh) 2009-05-27 2017-10-17 西莱克塔生物科技公司 具有不同释放速率的纳米载体加工组分
WO2010149745A1 (en) * 2009-06-24 2010-12-29 Glaxosmithkline Biologicals S.A. Recombinant rsv antigens
HRP20220756T1 (hr) * 2009-07-15 2022-09-02 Glaxosmithkline Biologicals S.A. Proteinski pripravci rsv f i postupci za izradu istih
HUE034247T2 (en) 2010-11-05 2018-02-28 Novavax Inc Rabies glycoprotein virus-like particles (VLP-K)
EP2729168A2 (en) * 2011-07-06 2014-05-14 Novartis AG Immunogenic compositions and uses thereof
SG10201602434UA (en) 2011-09-30 2016-05-30 Novavax Inc Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
RU2015138530A (ru) 2013-02-11 2017-03-20 Новавакс, Инк. Комбинированная вакцина против респираторно-синцитиального вируса и вируса гриппа
PL2988780T3 (pl) 2013-04-25 2019-06-28 Janssen Vaccines & Prevention B.V. Stabilizowane rozpuszczalne prefuzyjne polipeptydy F RSV
AU2014100888A4 (en) 2014-08-07 2014-09-11 Novartis Ag Virus clearance and protein purification methods
WO2017000105A1 (zh) * 2015-06-29 2017-01-05 尚平 便携式加湿器
CN114796474A (zh) 2015-09-03 2022-07-29 诺瓦瓦克斯股份有限公司 具有改进的稳定性和免疫原性的疫苗组合物

Also Published As

Publication number Publication date
CN102307591A (zh) 2012-01-04
JP2012511579A (ja) 2012-05-24
US20190134187A1 (en) 2019-05-09
JP2018007655A (ja) 2018-01-18
PL3067064T3 (pl) 2020-11-02
DK2370099T3 (en) 2016-08-01
EP3718566A1 (en) 2020-10-07
DK3067064T3 (da) 2020-06-08
KR101691574B1 (ko) 2017-01-02
WO2010077717A1 (en) 2010-07-08
US9731000B2 (en) 2017-08-15
HK1161690A1 (zh) 2012-08-03
PT2370099T (pt) 2016-07-14
JP5813513B2 (ja) 2015-11-17
US20150359872A1 (en) 2015-12-17
US9675685B2 (en) 2017-06-13
CY1123152T1 (el) 2021-10-29
SG10201500161XA (en) 2015-03-30
US20140294879A1 (en) 2014-10-02
EP2370099B1 (en) 2016-04-20
PL2370099T3 (pl) 2016-10-31
BRPI0922867B8 (pt) 2021-05-25
SI2370099T1 (sl) 2016-08-31
HUE051666T2 (hu) 2021-03-29
US20100239617A1 (en) 2010-09-23
HUE029037T2 (en) 2017-01-30
EP3718566B1 (en) 2024-06-12
HRP20200871T1 (hr) 2020-10-30
EP3067064A1 (en) 2016-09-14
MX358836B (es) 2018-09-05
KR20160148720A (ko) 2016-12-26
AU2009333484B2 (en) 2014-12-11
US8715692B2 (en) 2014-05-06
SI3067064T1 (sl) 2020-09-30
US20150266930A1 (en) 2015-09-24
AU2009333484A1 (en) 2011-07-21
RU2531510C2 (ru) 2014-10-20
US20150265698A1 (en) 2015-09-24
IL213450A0 (en) 2011-07-31
ES2582005T3 (es) 2016-09-08
IL247341B (en) 2018-04-30
MX345700B (es) 2017-02-10
CN106146671A (zh) 2016-11-23
RU2011128371A (ru) 2013-01-20
KR101801213B1 (ko) 2017-11-24
PT3067064T (pt) 2020-06-16
EP3067064B1 (en) 2020-05-13
KR20110112328A (ko) 2011-10-12
JP6782289B2 (ja) 2020-11-11
CY1117757T1 (el) 2017-05-17
US11052146B2 (en) 2021-07-06
JP6162751B2 (ja) 2017-07-12
BRPI0922867B1 (pt) 2020-09-29
SG172022A1 (en) 2011-07-28
EP2370099A4 (en) 2013-05-29
CA2746228A1 (en) 2010-07-08
ES2796725T3 (es) 2020-11-30
US10022437B2 (en) 2018-07-17
CA2746228C (en) 2021-05-18
CN102307591B (zh) 2016-08-03
JP2019069982A (ja) 2019-05-09
JP2015171378A (ja) 2015-10-01
HRP20160859T1 (hr) 2016-09-23
IL213450B (en) 2018-02-28
MX2011006205A (es) 2011-09-01
LT3067064T (lt) 2020-09-10
MX337932B (es) 2016-03-28
JP6462048B2 (ja) 2019-01-30
EP2370099A1 (en) 2011-10-05
US9717786B2 (en) 2017-08-01
CN106146671B (zh) 2020-03-31
US20230293667A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
BRPI0922867A2 (pt) proteina de fusao (f) de virus sincicial respiratorio (rsv) e metodos para seu uso
BRPI1008740A2 (pt) Proteínas pesticidas e métodos para seu uso.
BRPI0813216A2 (pt) Inibidores de proteínas cinases e métodos para usá-los.
BRPI0918947A2 (pt) proteína de fusão de anticorpo
BRPI0811635A2 (pt) Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
BRPI0822191A2 (pt) Método para caracterizar um reservatório de interesse, e sistema para caracterizar um reservatório de interesse
BRPI0907483A2 (pt) Cartucho de filtro e método para produzir e utilizar o mesmo
BRPI0910851A2 (pt) métodos e sistemas para protocolos de harq
BRPI0924183A2 (pt) inibidores de proteína quinase, formas cristalinas, formulações farmacêuticas e uso
BRPI0813985A2 (pt) anticorpos humanos para cd20 humana e método para seu uso.
BR112012001666A2 (pt) composições de proteína rsv f e métodos para fazer as mesmas
BRPI0915960A2 (pt) antígenos de polipeptídeos do vírus sincicial respiratório qimérico
BRPI0918359A2 (pt) composto, composição agroquímica, uso da composição agroquímica e método para preparação do composto
BRPI0911209A2 (pt) compósito elástico tendo elasticidade trans-direcional e um sistema e um método para fabricação deste compósito elástico
DK2464664T3 (da) Antistoffer mod humant respiratorisk syncytialvirus (rsv) og fremgangsmåder til anvendelse deraf
BRPI1011572A2 (pt) Glico-oligossacarídeos compreendendo ligações glicosídias (alfa1-4) e (alfa1-6), seu uso, e métodos para o seu fornecimento
BRPI0807480A2 (pt) Ligando, imunoglobulina g, composição e proteína de fusão
BRPI0919199A2 (pt) suspensões farmacêuticas submicrométricas estabilizadas e métodos para preparas as mesmas
BRPI0819210A2 (pt) Anticorpos de proteína g anti-rsv
BRPI0817257A2 (pt) Anticorpos moniclonais para vírus sincital respiratório e usos dos mesmos
BRPI0819970A2 (pt) "polipropileno expandido ecológico e método para o preparo de polipropileno expandido ecológico"
DK2099479T3 (da) Salmonella-vaccine i fjerkræ
BRPI0722092A2 (pt) Proteínas de plantas antifúngicas e métodos para seu uso
BRPI0916744A2 (pt) filtro de fluxo direto e método para fazer o mesmo
BRPI0808813A2 (pt) método para a preparação de compostos de borracha, e, uso de compostos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/12/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF